**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A ~~**sustained-release**~~ pharmaceutical composition in a form of an orally deliverable**, sustained-release** tablet comprising ~~**an active pharmaceutical agent having solubility not less than about 10mg/ml**~~ **reboxetine, or a pharmaceutically acceptable salt thereof**, dispersed in a matrix comprising a hydrophilic polymer and a starch **having, wherein the starch has** a tensile strength of at least ~~**about**~~ 0.15 kN $cm^{-2}$ at a solid fraction ~~**representative of the tablet**~~ **of 0.75 to 0.85**.

2. (Currently Amended) The composition of Claim 1 wherein the starch has a tensile strength of at least **about** 0.175 kN $cm^{-2}$ at a solid fraction ~~**representative of the tablet**~~ **of 0.75 to 0.85**.

3. (Currently Amended) The composition of Claim 1 wherein the starch has a tensile strength of at least **about** 0.2 kN $cm^{-2}$ at a solid fraction ~~**representative of the tablet**~~ **of 0.75 to 0.85**.

4. (Previously Presented) The composition of Claim 1 wherein the starch is a pregelatinized starch.

5. (Currently Amended) The composition of Claim 1 wherein the starch is present in an amount of about 25% to about 75% by weight **of the tablet**.

6. (Currently Amended) The composition of Claim 1 wherein the starch is present in an amount of about 40% to about 70% by weight **of the tablet**.

7. (Currently Amended) The composition of Claim 1 wherein the starch is present in an amount of about 45% to about 65% by weight **of the tablet**.

8. (Previously Presented) The composition of Claim 1 wherein the hydrophilic polymer is selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, carmellose sodium and carbomer.

9. (Previously Presented) The composition of Claim 1 wherein the hydrophilic polymer is hydroxypropylmethylcellulose.

10. (Currently Amended) The composition of Claim 1 wherein the hydrophilic polymer is present in an amount of about 20% to about 70% by weight **of the tablet**.

11. (Currently Amended) The composition of Claim 1 wherein the hydrophilic polymer is present in an amount of about 30% to about 60% by weight **of the tablet**.

12. (Currently Amended) The composition of Claim 1 wherein the hydrophilic polymer is present in an amount of about 35% to about 50% by weight **of the tablet**.

13-21. (Cancelled).

22. (Currently Amended) The composition of Claim ~~13~~ **1** wherein the ~~active pharmaceutical agent is a salt of reboxetine or an enantiomer thereof~~ **reboxetine, or a pharmaceutically acceptable salt thereof, is (S,S)-reboxetine, or a pharmaceutically acceptable salt thereof**.

23. (Currently Amended) The composition of Claim ~~13~~ **22** wherein the ~~active pharmaceutical agent~~ **(S,S)-reboxetine, or a pharmaceutically acceptable salt thereof,** is (S,S)-reboxetine succinate.

24. (Currently Amended) The composition of Claim ~~13~~ 1 that comprises 0.2 to 15 mg reboxetine per tablet.

25. (Currently Amended) The composition of Claim ~~13~~ 1 that comprises 1 to 12 mg reboxetine per tablet.

26. (Previously Presented) The composition of Claim 1, further comprising a coating on the tablet.

27. (Previously Presented) The composition of Claim 26 wherein said coating is a release-controlling layer.

28. (Previously Presented) The composition of Claim 27 wherein said release-controlling layer constitutes 1% to 15% by weight of the tablet.

29. (Previously Presented) The composition of Claim 26 wherein said coating is a nonfunctional coating.

30. (Currently Amended) A pharmaceutical composition in a form of an orally deliverable tablet, comprising (S,S)-reboxetine succinate dispersed in a matrix comprising (a) HPMC in an amount of 35% to 50% by weight of the tablet and (b) a ~~pre-gelatinised~~ **pregelatinized** starch having a tensile strength of at least ~~about~~ 0.15 kN $cm^{-2}$ at a solid fraction of 0.8, in an amount of 45% to 65% by weight of the tablet.

31. (Withdrawn) A method of treatment of a subject having a **central nervous system** condition or disorder for which ~~an active pharmaceutical agent having solubility not less than about 10mg/ml~~ **reboxetine, or a pharmaceutically acceptable salt thereof**, is indicated, wherein:

the method ~~comprising~~ **comprises** orally administering to the subject the pharmaceutical composition of claim 1.

32-34. (Cancelled).

35. (Withdrawn) The method of Claim ~~34~~ **31** wherein the ~~selective noradrenaline reuptake inhibitor~~ **reboxetine, or a pharmaceutically acceptable salt thereof**, is (S,S)-reboxetine succinate.

36. (Cancelled).

37. (Currently Amended) A process for preparing a ~~sustained-release~~ pharmaceutical composition **according to Claim 1** in a form of an orally deliverable, **sustained-release** tablet, the process comprising selecting by a suitable test a starch having a tensile strength of at least **about** 0.15 kN $cm^{-2}$ at a solid fraction ~~representative of the tablet~~ **of 0.75 to 0.85**; admixing with the selected starch a hydrophilic polymer and ~~an active pharmaceutical agent having solubility not less than about 10mg/ml~~ **reboxetine, or a pharmaceutically acceptable salt thereof**, to provide a mixture wherein the ~~agent~~ **reboxetine, or a pharmaceutically acceptable salt thereof,** is dispersed in a matrix comprising the polymer and the starch; and compressing the mixture to form said tablet.

38-47. (Cancelled).

48. (New) The composition of Claim 2 wherein the reboxetine, or a pharmaceutically acceptable salt thereof, is (S,S)-reboxetine, or a pharmaceutically acceptable salt thereof.

49. (New) The composition of Claim 3 wherein the reboxetine, or a pharmaceutically acceptable salt thereof, is (S,S)-reboxetine, or a pharmaceutically acceptable salt thereof.

50. (New) The composition of Claim 4 wherein the reboxetine, or a pharmaceutically acceptable salt thereof, is (S,S)-reboxetine, or a pharmaceutically acceptable salt thereof.

51. (New) The composition of Claim 5 wherein the reboxetine, or a pharmaceutically acceptable salt thereof, is (S,S)-reboxetine, or a pharmaceutically acceptable salt thereof.

52. (New) The composition of Claim 6 wherein the reboxetine, or a pharmaceutically acceptable salt thereof, is (S,S)-reboxetine, or a pharmaceutically acceptable salt thereof.

53. (New) The composition of Claim 7 wherein the reboxetine, or a pharmaceutically acceptable salt thereof, is (S,S)-reboxetine, or a pharmaceutically acceptable salt thereof.

54. (New) The composition of Claim 8 wherein the reboxetine, or a pharmaceutically acceptable salt thereof, is (S,S)-reboxetine, or a pharmaceutically acceptable salt thereof.

55. (New) The composition of Claim 9 wherein the reboxetine, or a pharmaceutically acceptable salt thereof, is (S,S)-reboxetine, or a pharmaceutically acceptable salt thereof.

56. (New) The composition of Claim 10 wherein the reboxetine, or a pharmaceutically acceptable salt thereof, is (S,S)-reboxetine, or a pharmaceutically acceptable salt thereof.

57. (New) The composition of Claim 11 wherein the reboxetine, or a pharmaceutically acceptable salt thereof, is (S,S)-reboxetine, or a pharmaceutically acceptable salt thereof.

58. (New) The composition of Claim 12 wherein the reboxetine, or a pharmaceutically acceptable salt thereof, is (S,S)-reboxetine, or a pharmaceutically acceptable salt thereof.